Pro Forma Revenues of $18.5 Million , up 22% From Previous Quarter
NEW YORK and TORONTO , May 30, 2019 /CNW/ - iAnthus Capital Holdings, Inc. ("iAnthus" or the "Company") (CSE: IAN, OTCQX: ITHUF), which owns, operates, and partners with best-in-class regulated cannabis operations across the United States , is pleased to report its financial results for the fiscal first quarter ended March 31, 2019 . Amounts are in U.S. Dollars, unless stated otherwise.
On February 5, 2019 , the Company closed the plan of arrangement with MPX. The landmark transaction was the first public-to-public merger and the largest closed transaction to date for a multi-state operator in the US cannabis sector. The transaction expanded the Company's platform to 11 states.
Hadley Ford , CEO of iAnthus, provided the following statement on the Company's first quarter results and outlook for 2019:
"2019 is off to a great start for team iAnthus, and I want to thank all of our dedicated employees for their hard work as we fully integrate the MPX and iAnthus operations. Revenues in the first quarter are up 22% sequentially on a pro forma basis for the combined company and that pace has accelerated into April and May. We are excited to be moving forward on our branding initiatives and look forward to opening our first flagship Be. store in Brooklyn this fall. Momentum is continuing across all our markets, particularly in our greenfield operations in Maryland , Massachusetts , and Florida . We expect to close the CBD For Life acquisition shortly and can't wait to share some of the exciting plans in store for that business. Managing growth is our number one focus, and we remain committed to investing prudently in our business to take advantage of this once ever opportunity. We will continue to be opportunistic in our approach to M&A and will maintain a strong focus on reducing our overall cost of capital. We are very excited about 2019 and look forward to continuing to deliver for our shareholders."
Financial Highlights
Revenue
See Tables 1 and 2 below for further detail
Gross Profit
See Table 3 below for further detail
EBITDA and Net Income
See Table 3 below for further detail
Balance Sheet
Operational and Branding Updates
Be. The Cannabis Store
On May 14, 2019, the Company announced its new retail brand "Be." The first flagship Be. store is under construction in Brooklyn , and the Company anticipates a grand opening in the fall of this year. New flagship stores in Miami , Las Vegas and Atlantic City will follow. iAnthus' existing stores will be prioritized and gradually retrofit to Be. stores. Please see the Be. press release and announcement video.
MPX
MPX's award winning products are distributed in over 110 stores across the US. Our MPX concentrate and resin product lines continue to attract acclaim from both wholesale and retail customers. In addition to the Company's core MPX product lines, the Company is preparing to launch several complementary product lines. The Company is in the final stages of developing a "fighter brand" concentrate product line that will be marketed to both retail patients and wholesale clients. Within Arizona, the Company is also about to launch a live resin collaboration with one of the most renowned cultivators within the state and will continue to keep the market informed as to new product developments. The Company anticipates opening a second cultivation and processing facility in Massachusetts in late 2019 that will include hydrocarbon extraction equipment and enable the production of MPX products in the state.
CBD For Life
iAnthus expects to close the acquisition of CBD For Life, a top-ranked, national CBD brand in the U.S in early June. CBD For Life is now available in over 1,000 doors nationwide including new distribution relationships with national and specialty retailers such as Urban Outfitters (online and 6 flagship stores), Of a Kind, and Exhale Spa. In addition, CBD For Life will be rolling out a premium product line and an adult line during this summer.
Massachusetts
The Company's Holliston cultivation facility has continued to see operational efficiencies and recorded current cash cultivation cost of $1.24 8 per gram during the quarter. The Company recorded over $2.0 million of revenue during the month of April 2019 , surpassing the revenue for the first three months combined. Wholesale demand remains strong, with products sold in 15 dispensaries throughout the state. The Company is currently in negotiations with Allston (situated within the City of Boston ) over terms of its host agreement for an adult use license at its existing medical-only facility and the Company continues to expect that dispensary will be operating under an adult-use license in 2019. Further, two additional dispensaries, in Worcester and Lowell , are targeted to open under adult-use licenses later this year.
Florida
The Company's Lake Wales cultivation facility now has approximately 120,000 square feet in operation, of which 70,000 square feet is in a lower cost cultivation environment. The 33-acre campus has significant room for expansion, in both indoor and outdoor capabilities that will be announced throughout 2019. The Company is operating three dispensaries and is planning to open an additional three dispensaries within the next 45 days. Based on the latest reports of state-wide sales from the Office of Medical Marijuana Use, the Company is ranked third of all Florida operators in terms of THC milligrams sold per dispensary.
Maryland
Driven by its market leading processing capabilities and products, the Company continues to show strength in both its retail and wholesale operations. The Company's extraction footprint is being increased to over 3,000 square feet, which will increase its production capabilities over 200% from current levels. In Maryland, MPX products are now available in 51 of 72 retail dispensaries.
Arizona and Nevada
In the Southwest region, the Company's wholesale offerings continued to be strongly received in both markets, selling to approximately 40 dispensaries per month in the first quarter, and 46 in April 2019. Average size of wholesale orders has increased by 100% in Nevada and 25% in Arizona since the first quarter of 2018. On May 29, 2019 , the Arizona Supreme Court ruled in favor of the medical marijuana industry and patients who choose to use cannabis extracts such as vape cartridges, edibles, waxes and tinctures. Extracts form a significant portion of the Arizona medical use market and the court's 7-0 ruling reflects the overwhelming support in the market for continued access to these products. The Company's four Arizona dispensaries are also preparing for the launch of several new concentrate product lines.
New York
The Company opened two dispensaries in the first quarter of 2019, and has signed a lease for its third dispensary, located on Staten Island . This will be the only licensed dispensary serving Staten Island's 500,000 residents and is expected to open in the fourth quarter of this year. The Company eagerly awaits further clarity as to the development of both the medical and recreational programs within the state in order to refine its capital expenditure program.
Table 1: Unaudited Reported Financial Highlights |
||||
in thousands of US$, except share and per share amounts (unaudited) |
Q1 2019 |
Q1 2018 |
||
Reported revenues |
$ |
9,620 |
$ |
225 |
Gross profit, excluding fair value items |
540 |
185 |
||
Gross margin, excluding fair value items |
5.6% |
82.3% |
||
Net loss |
(18,265) |
(645) |
||
Net loss per share |
(0.15) |
(0.01) |
Table 2: Unaudited Pro Forma Revenues |
||||
in thousands of US$ (unaudited) |
Q1 2019 |
Q4 2018 |
||
Reported Revenues |
$ |
9,620 |
$ |
1,986 |
Pro forma Adjustments(1): |
||||
MPX Bioceutical Corporation (2) |
3,149 |
11,640 |
||
CBD For Life |
714 |
632 |
||
Managed Revenues (1) |
5,061 |
993 |
||
Total Pro forma Revenues(1): |
$ |
18,544 |
$ |
15,251 |
Table 3: Unaudited Adjusted EBITDA Highlights |
||||
in thousands of US$, except share and per share amounts (unaudited) |
Q1 2019 |
Q4 2018 |
||
Reported Revenues |
$ |
9,620 |
1,986 |
|
Cost of Sales |
(9,080) |
(1,353) |
||
Fair value adjustment on inventory from acquisition (3) |
1,709 |
- |
||
Realized fair value adjustment on biological assets (4) |
1,198 |
842 |
||
Adjusted gross profit |
3,447 |
1,475 |
||
Adjusted gross margin |
35.8% |
74.3% |
||
Unrealized fair value adjustment on biological assets |
3,821 |
1,285 |
||
Total adjusted gross profit |
7,268 |
2,759 |
||
Operating expenses |
(23,165) |
(15,652) |
||
Other Items |
(659) |
(3,033) |
||
Adjusted net loss |
(16,556) |
(15,926) |
||
Income tax expense |
668 |
608 |
||
Interest expense |
2,346 |
1,331 |
||
Depreciation and amortization |
2,636 |
4,553 |
||
EBITDA (Non-IFRS) |
(10,906) |
(9,434) |
||
Adjusting items: |
||||
Share-based compensation |
1,646 |
1,841 |
||
Accretion expense |
1,515 |
812 |
||
Fair market value adjustments |
(3,210) |
(559) |
||
Foreign exchange loss |
- |
1,055 |
||
Profit from investment in associate |
(73) |
(170) |
||
Adjustment for one-time acquisition costs (5) |
5,173 |
- |
||
Non-cash inventory adjustment (6) |
720 |
- |
||
Adjusted EBITDA(7) |
(5,135) |
(6,455) |
||
Adjusted EBITDA(7) per share |
(0. |